Expression of OLR1 gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome.

IF 7.2 2区 医学
Peng Zhang, Yan Zhao, Xin Xia, Song Mei, Yixuan Huang, Yingying Zhu, Shuting Yu, Xingming Chen
{"title":"Expression of <i>OLR1</i> gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome.","authors":"Peng Zhang,&nbsp;Yan Zhao,&nbsp;Xin Xia,&nbsp;Song Mei,&nbsp;Yixuan Huang,&nbsp;Yingying Zhu,&nbsp;Shuting Yu,&nbsp;Xingming Chen","doi":"10.1080/2162402X.2023.2203073","DOIUrl":null,"url":null,"abstract":"<p><p>Head and neck squamous cell carcinoma (HNSCC) is one of the most heavily immune infiltrated human tumors, having distinct immune subtypes associated with different molecular characteristics and clinical outcomes. The tumor microenvironment (TME) of HNSCC which was dominated by tumor-associated macrophages (TAMs) had a relatively inferior prognosis. High levels of oxidized low-density lipoprotein receptor 1 (<i>OLR1</i>) expression are associated with more aggressive and metastatic characteristics in multiple cancers. However, the link between the <i>OLR1</i> expression and immunosuppression of TME, and the molecular mechanisms which govern intratumoral TAMs behavior are unclear. Here, we performed the transcriptional analysis based on a single-cell RNA-sequencing (scRNA-seq) dataset of HNSCC, and found that the <i>OLR1</i> expression was specifically enriched on the TAMs. Evaluation of protein expression within histologic sections of primary HNSCC patient samples showed a co-expression pattern of <i>OLR1</i> and <i>CD68</i> on macrophages. A total of 498 tumor samples of HNSCC patients from The Cancer Genome Atlas (TCGA) database were also analyzed. Remarkably, <i>OLR1</i> expression was dramatically higher in HNSCC tissues than that in adjacent normal tissues, and the patients with high levels of <i>OLR1</i> expression had significantly unfavorable overall survival (Hazard Ratio = 1.724, log-rank <i>P</i>-value = 0.0066) when compared to patients harboring low expression levels of <i>OLR1</i>. In summary, we reported that the specific expression of <i>OLR1</i> on the TAMs was significantly correlated with poor survival outcomes, revealing that <i>OLR1</i> could serve as a potential prognosis marker and promising target for immunotherapy in HNSCC.</p>","PeriodicalId":19683,"journal":{"name":"Oncoimmunology","volume":"12 1","pages":"2203073"},"PeriodicalIF":7.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/c2/KONI_12_2203073.PMC10120517.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402X.2023.2203073","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Head and neck squamous cell carcinoma (HNSCC) is one of the most heavily immune infiltrated human tumors, having distinct immune subtypes associated with different molecular characteristics and clinical outcomes. The tumor microenvironment (TME) of HNSCC which was dominated by tumor-associated macrophages (TAMs) had a relatively inferior prognosis. High levels of oxidized low-density lipoprotein receptor 1 (OLR1) expression are associated with more aggressive and metastatic characteristics in multiple cancers. However, the link between the OLR1 expression and immunosuppression of TME, and the molecular mechanisms which govern intratumoral TAMs behavior are unclear. Here, we performed the transcriptional analysis based on a single-cell RNA-sequencing (scRNA-seq) dataset of HNSCC, and found that the OLR1 expression was specifically enriched on the TAMs. Evaluation of protein expression within histologic sections of primary HNSCC patient samples showed a co-expression pattern of OLR1 and CD68 on macrophages. A total of 498 tumor samples of HNSCC patients from The Cancer Genome Atlas (TCGA) database were also analyzed. Remarkably, OLR1 expression was dramatically higher in HNSCC tissues than that in adjacent normal tissues, and the patients with high levels of OLR1 expression had significantly unfavorable overall survival (Hazard Ratio = 1.724, log-rank P-value = 0.0066) when compared to patients harboring low expression levels of OLR1. In summary, we reported that the specific expression of OLR1 on the TAMs was significantly correlated with poor survival outcomes, revealing that OLR1 could serve as a potential prognosis marker and promising target for immunotherapy in HNSCC.

Abstract Image

Abstract Image

Abstract Image

OLR1基因在头颈部鳞状细胞癌肿瘤相关巨噬细胞中的表达及其与临床预后的关系
头颈部鳞状细胞癌(HNSCC)是免疫浸润程度最高的人类肿瘤之一,具有不同的免疫亚型,与不同的分子特征和临床结果相关。HNSCC的肿瘤微环境(TME)以肿瘤相关巨噬细胞(tam)为主,预后相对较差。在多种癌症中,高水平的氧化低密度脂蛋白受体1 (OLR1)表达与更具侵袭性和转移性特征相关。然而,OLR1表达与TME免疫抑制之间的联系,以及控制肿瘤内TME行为的分子机制尚不清楚。在这里,我们基于HNSCC的单细胞rna测序(scRNA-seq)数据集进行转录分析,发现OLR1表达在tam上特异性富集。对原发性HNSCC患者样本的组织学切片中蛋白表达的评估显示,巨噬细胞上存在OLR1和CD68的共表达模式。同时对来自癌症基因组图谱(TCGA)数据库的498例HNSCC患者的肿瘤样本进行分析。值得注意的是,OLR1在HNSCC组织中的表达明显高于邻近正常组织,并且OLR1高表达的患者与OLR1低表达的患者相比,总体生存期明显不利(风险比= 1.724,log-rank p值= 0.0066)。综上所述,我们报道了OLR1在tam上的特异性表达与不良生存结果显著相关,这表明OLR1可以作为HNSCC潜在的预后标志物和有希望的免疫治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncoimmunology
Oncoimmunology ONCOLOGY-IMMUNOLOGY
CiteScore
12.80
自引率
2.80%
发文量
276
期刊介绍: Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信